THERMOGENESIS - 60%!!!! - 500 Beiträge pro Seite

[KnechtRuprecht]

Hallo Leute,
nach der Empfehlung von THERMOGENESIS (883496)in der gestrigen Telebörsem ist der Kurs um über 60 % gestiegen.

Glückwunsch an die, die clever waren und sich welche ins Depot gepackt haben. Ich habe gepennt.

Hasta luego
KnechtRuprecht

[Braini]

abwarten was amiland macht... das is sicher top für die die hoch verkaufen konnten jetzt... aber 60% für ne empfehlung in ntv... die kurse werden doch eher in amerika gemacht. bin ich mal gespannt wie das heut nachmittag weiter geht

[dollarboy]

Ihr werdet ganz schön auf die Nase fallen!!! Hab ihr euch mal den Chart angesehen??????
Anscheinend nicht!!!

[TheCooolman]

Das heute Morgen waren Zocker. Die haben zu ca. 70 % Aufgeld gekauft.
Die eher <nüchternen> Strategen warten mal ab.
Ich denke das Aufgeld wird reduziert...
Cooolman

[mehrcash]

Die kriegt man spätestens morgen wieder für unter 4 Euro.

[TOMCOOL]

Jeder der die Aktie im Moment für mehr als 4.50 gekauft (Eröffnungskurs heute) sollte diese jetzt Verkaufen.
Das sind alles nur Zocker und der Wert wird in den USA gemacht.
Wir werden sehen was sich um 15:30 Uhr tut.
Das Papier sinkt im moment ziemlich schnell von 5.80 bis auf
aktuell 12:47 Uhr 4.90

[Michael16]

THERMOGENESIS CORP. Announces Issuance of Latest Patent for Device to Isolate Stem
Cells From Blood


MONDAY, SEPTEMBER 25, 2000 6:14 AM
- BusinessWire

RANCHO CORDOVA, Calif., Sep 25, 2000 (BW HealthWire) -- THERMOGENESIS CORP. (NasdaqNM:KOOL)
announced today that it has received notice from the U.S. Patent Office of the issuance of a patent describing a
disposable bag set configured to isolate a stem cell rich fraction of blood into a fixed volume during centrifugation.
THERMOGENESIS` patent portfolio includes 15 issued and eight pending U.S. patents.

Dr. James Godsey, President and COO of THERMOGENESIS CORP., noted that this improved bag set could be
integrated into the BioArchive System of devices and disposals for processing hematopoietic stem cells from
placental/umbilical cord blood (PCB). BioArchive Systems are currently in use at the major cord blood banks in
Japan, China, Taiwan, Vietnam, Germany, Spain, Finland, U.K., Belgium and the U.S.

The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing
and validation of stem cell units. It uses a computer-driven robotic system to archive up to 3,626 PCB stem cell units
in liquid nitrogen at -196 degrees C that have been collected and processed in proprietary sterile plastic bag sets.
The BioArchive System performs a precise controlled-rate freeze, tracks identification and archive location and
performs robotic storage and retrieval of each unique tissue-typed PCB unit for use in life-saving transplantation. A
specialized transfusion bag set is used to administer the stem cells to the patient. The BioArchive System can
freeze, place and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient
warming events (TWE) which can reduce cell viability. PCB stem cells are used to reconstitute the hematopoietic
and immune systems of patients who have undergone high-dose chemotherapy and radiation to combat diseases
such as leukemias, lymphomas, diverse inherited anemias and hypoproliferative stem cell disorders.

According to Philip Coelho, Chairman and CEO of the Company, "Recent research suggests that there are stem
cells in a unit of cord blood that have the potential to produce other cells outside the hematopoietic system such as
neural, liver and bone cells. Since there are serious ethical issues with sourcing stem cells from embryos and
fetuses, scientists may begin to focus on cord blood as a superior, non-controversial source for stem cells." The
BioArchive System has additional potential applications involving archiving, storing, managing and retrieving of other
kinds of biological specimens, including peripheral blood-derived stem-cells, cell lines, male sperm cells, female
eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples.

Regulatory Status

The BioArchive System is a Class II exempt blood component freezer, and has initially been distributed in the U.S.
only to IND sites which have received FDA approvals for use with stem cell storage for transplant into unrelated
patients. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other
kinds of biological specimens, that may include peripheral blood-derived stem-cells, cell lines, male sperm cells,
female eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The
BioArchive System is currently intended for preservation of blood components and blood products and would require
FDA 510(k) clearance for some additional claims.

About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect,
cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.

The statements contained in this release which are not historical facts are forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to
market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks
detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

CONTACT: THERMOGENESIS CORP.
James H. Godsey, Ph.D., 916/858-5100
[e-mail]
www.thermogenesis.com

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.